MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jhin.2026.09.010

Медицинская библиотека · The Journal of hospital infection · 2026

Economic evaluation of enhanced oral care in reducing the incidence of non-ventilator hospital-acquired pneumonia.

Sharma Pakhi, White Nicole M, Graves Nicholas, Stewardson Andrew J, Cheng Allen C, Russo Philip L, Matterson Georgia, Tehan Peta E, Browne Katrina, Kiernan Martin, Mitchell Brett G

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The Hospital-Acquired Pneumonia PrEveNtion (HAPPEN) trial evaluated the effectiveness and cost-effectiveness of improving oral care on reducing non-ventilator hospital-acquired pneumonia (NV-HAP). This study aimed to assess the cost-effectiveness of the HAPPEN intervention compared with usual care.

METHODS

The HAPPEN trial was a cluster randomised controlled trial conducted across three Australian hospitals. A within trial economic evaluation was undertaken from a hospital perspective using an intention to treat approach. Cost-effectiveness was estimated using a cohort-level decision analytic model incorporating intervention implementation costs and bed day costs associated with NV-HAP treatment. Costs were reported in 2025 Australian dollars (AUD). Health outcomes were measured in quality-adjusted life years (QALYs). Trial data and published literature informed model parameters. Outcomes were reported using net monetary benefit. Probabilistic sensitivity analysis was conducted at a willingness to pay threshold of AUD$28,000 per QALY.

RESULTS

For a cohort of 1,000 patients, usual care were estimated at AUD$12,148,000, compared with AUD$11,996,000 for the intervention after accounting for bed days saved. These estimates corresponded to a saving of AUD$152 and 0.02 QALY gained per patient, supporting the HAPPEN intervention as dominant. A positive incremental net monetary benefit of AUD$642 (95% uncertainty interval AUD$42 to AUD$1,591) per patient indicated the intervention as a cost-effective strategy. Probabilistic sensitivity analysis showed the intervention had approximately 98% probability of being cost-effective at the AUD$28,000 willingness to pay threshold.

CONCLUSION

Improved oral care in the HAPPEN trial was cost-effective, reducing NV-HAP and associated hospital costs, supporting its adoption as an infection prevention strategy.

Для цитирования: Sharma Pakhi, White Nicole M, Graves Nicholas, Stewardson Andrew J, Cheng Allen C, Russo Philip L, Matterson Georgia, Tehan Peta E, Browne Katrina, Kiernan Martin, Mitchell Brett G. Economic evaluation of enhanced oral care in reducing the incidence of non-ventilator hospital-acquired pneumonia.. The Journal of hospital infection. 2026. DOI: 10.1016/j.jhin.2026.09.010.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.